- Spyre Therapeutics (SYRE) announced an underwritten public offering of common stock.
- Underwriters have a 30-day option to purchase an additional 15% of shares.
- Proceeds will fund pipeline programs in Gastroenterology, Rheumatology, and Dermatology, including SPY072 for hidradenitis suppurativa.
- Jefferies, TD Cowen, Leerink Partners, and Stifel are joint book-running managers; LifeSci Capital is passive bookrunner.
- The offering is subject to market conditions.
- A registration statement on Form S-3 (File No. 333-297063) became effective June 26, 2026.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card